Published 07 June 2011 | By INC Research
A perfect storm is forming within the biopharmaceutical industry. With a growing number of blockbuster drugs losing patent protection, clinical research executives are under immense pressure to bring new drugs to market. As sponsor companies struggle to replace the revenue loss threatened by generics, drug development is becoming more complex and expensive.
